OMER enters its August 13 earnings release having rallied 33% in a month, yet the borrow market tells a starkly different story from the price action — the lending pool is effectively exhausted.
Availability has collapsed to just 1.1% of shares available to borrow, meaning for every 90 shares already out on loan, fewer than one remains available to new short sellers. That tightness has been persistent: availability dipped to zero on multiple sessions through July and into August, and the borrow market has been at or near full capacity for most of the past six weeks. Short interest reinforces the scale of bearish positioning. More than 21% of the free float is sold short, with around 15.2 million shares borrowed as of August 11 — well off the early-July peak near 18 million but still among the highest readings in the stock's recent history. Days to cover run close to ten. Cost to borrow, at 2.35%, remains relatively modest given the squeeze conditions — it eased roughly 18% on the week — suggesting the borrow market is constrained by supply rather than a spike in demand. Options positioning, by contrast, looks lighter on defense than usual: the put/call ratio of 0.47 runs below its 20-day average of 0.52, a mildly bullish tilt heading into the print.
The fundamental debate centres on YARTEMLEA, Omeros's first-approved therapy for TA-TMA, and how much competitive risk the market is pricing in. Bulls point to early launch momentum, a permanent J-code and NTAP approval from CMS, broad formulary access, and a partnership with Novo Nordisk as evidence that YARTEMLEA is carving out a durable commercial position. The pipeline — including OMS1029 and OMS527 — adds further optionality. Bears have focused on the overhang from AstraZeneca's ravulizumab data in TA-TMA, which was expected around EHA and ISTH conference windows earlier this summer, and whether a positive competitive readout could slow YARTEMLEA's uptake or compress reimbursement. Coverage is thin: HC Wainwright trimmed its target to $33 from $40 in late June while keeping a Buy rating, and D. Boral Capital holds at $36 with a Buy. Both targets sit well above the current $13.71 price, though that gap partly reflects the stock's recent collapse from higher levels rather than a fresh bullish push. The analyst consensus was struck 48 days ago, making it modestly stale relative to this week's print.
Institutional ownership adds one notable detail. Vanguard Capital Management entered the register as of June 30, accumulating a full 3.5 million share position — roughly 4.8% of shares outstanding — in a single reporting period. BlackRock added 735,000 shares through July 31, lifting its stake to 8.4%. That institutional accumulation runs against the insider picture: the CEO sold 357,678 shares in February at $11.93, and the Chief Accounting Officer sold 60,000 shares in January. Those sales occurred close to current price levels, meaning insiders were not holding for the subsequent recovery.
The print will test whether YARTEMLEA's revenue trajectory is strong enough to justify a stock trading at roughly 40 cents on the dollar relative to where analysts set their targets — and whether the commercial story has developed enough momentum to begin absorbing the short position that has dominated this name all year.
See the live data behind this article on ORTEX.
Open OMER on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
